Crescent Biopharma (CBIO) Liabilities and Shareholders Equity (2013 - 2026)

Crescent Biopharma (CBIO) has 14 years of Liabilities and Shareholders Equity data on file, last reported at $199.1 million in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $199.1 million, up 3223.16% year-over-year; the trailing twelve-month figure through Mar 2026 was $735.1 million (up 799.5% YoY), and the FY2025 annual result was $240.3 million, up 574.66% from the prior year.
• Liabilities and Shareholders Equity eased to $199.1 million in Q1 2026 per CBIO's latest filing, from $240.3 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $240.3 million in Q4 2025 and troughed at $6.0 million in Q1 2025.
• A 5-year average of $78.5 million and a median of $56.0 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2025 and 2026: Liabilities and Shareholders Equity sank 82.48% in 2025, then soared 3223.16% in 2026.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $51.8 million in 2022, then slipped by 12.53% to $45.3 million in 2023, then fell by 21.4% to $35.6 million in 2024, then surged by 574.66% to $240.3 million in 2025, then dropped by 17.13% to $199.1 million in 2026.
• Business Quant data shows CBIO's Liabilities and Shareholders Equity at $199.1 million in Q1 2026, $240.3 million in Q4 2025, and $138.3 million in Q3 2025.